Trimetazidine dihydrochloride 13171-25-0

簡要描述：Trimetazidine dihydrochloride 13171-25-0
Trimetazidine dihydrochloride is a drug for angina pectoris.

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

查看全部

詳細介紹

品牌	absin	CAS	13171-25-0
分子式	C14H22N2O3.2HCl	純度	99%
分子量	339.26	貨號	abs47027432
規(guī)格	25mg	供貨周期	現(xiàn)貨
主要用途	is a drug for angina pectoris	應用領域	化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合

Trimetazidine dihydrochloride 13171-25-0

產(chǎn)品描述
描述	Trimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent , which improves myocardial glucose utilization through inhibition of fatty acid metabolism.
純度	99%
儲存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
別名	yan酸曲美他嗪
外觀	白色至淡黃色固體
可溶性/溶解性	DMSO : 67 mg/mL (197.49 mM) Water : 67 mg/mL (197.49 mM) Ethanol : 67 mg/mL (197.49 mM)
生物活性
靶點	mitochondrial long-chain 3-ketoacyl thiolase
In vitro(體外研究)	Trimetazidine up-regulates miR-21 expression, then miR-21 targets PTEN increasing the PI3K pathway and finally the activation of this pathway counteracts the apoptotic effect of hypoxia/reperfusion.
In vivo(體內(nèi)研究)	The administration of TMZ reduces myocardial infarction size in WT C57BL/6J hearts. Both AMPK and ERK signaling pathways mediate the cardioprotection of TMZ against ischemic injury. Trimetazidine Shifts Metabolism from Fatty Acid Oxidation to Glucose Oxidation and improves Contractile Functions of Cardiomyocytes during Hypoxia.
參考文獻
參考文獻	1. Kantor PF, et al. Circ Res. 2000 Mar 17;86(5):580-8. 2. Stanley WC, Marzilli M. Fundam Clin Pharmacol. 2003 Apr;17(2):133-45. 3. Sellier P, Broustet JP. Am J Cardiovasc Drugs. 2003;3(5):361-9.

研究領域
研究領域	Cardiovascular Drug DiscoverySmall Molecule DrugLead Compound Discovery

Trimetazidine dihydrochloride 13171-25-0溫馨提示：本產(chǎn)品僅作科研實驗使用，不支持臨床等研究

產(chǎn)品咨詢